SCHEMBL13650780

SCHEMBL13650780

C[Si](C)(C)c1cc(N)ccc1Br

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.37
MAPT P10636 4/20 0.37
KDM4E B2RXH2 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
ALOX15 P16050 1/20 0.35
MAPK1 P28482 1/20 0.35
CASP1 P29466 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
TP53 P04637 1/20 0.34
LMNA P02545 2/20 0.33
ACHE P22303 2/20 0.33
F2 P00734 1/20 0.33
CHRM2 P08172 1/20 0.33
HTR1A P08908 1/20 0.33
ADRA2A P08913 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
MAOA P21397 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19126026 0.76 HSP90AA1 (0.41) ALDH1A1ALOX15MAPK1LMNATSHR
SCHEMBL5718612 0.76 CASP1 (0.42) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL17866559 0.73 AHR (0.34) ALDH1A1NPC1RAB9AALOX15MAPK1
SCHEMBL9081266 0.73 PDE10A (0.52) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL17936111 0.73 CYP3A4 (0.52) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL8861704 0.73 ENPP2 (0.35) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL13668211 0.73 ALDH1A1 (0.36) ALDH1A1KDM4EMEN1KMT2ANPC1
SCHEMBL16600191 0.72 AHR (0.33)
SCHEMBL8861695 0.70 CA12 (0.40) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL632670 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090269354-A1 QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT CONCERT PHARMACEUTICALS, INC. (US) 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090269354-A1 QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT ABL1, FLT3, GRK5 ALDH1A1 3767/4885MAPT 2632/4885KDM4E 2268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.